Patents by Inventor Jonathan Pollock
Jonathan Pollock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11689603Abstract: Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.Type: GrantFiled: April 14, 2021Date of Patent: June 27, 2023Assignee: MOXIE SOFTWARE, INC.Inventors: Michael Galloway, Randy Nasson, Jonathan Lee Bell, Jonathan Pollock
-
Patent number: 11673898Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.Type: GrantFiled: July 30, 2020Date of Patent: June 13, 2023Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
-
Patent number: 11555041Abstract: The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: GrantFiled: July 13, 2020Date of Patent: January 17, 2023Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
-
Patent number: 11542248Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: GrantFiled: June 7, 2018Date of Patent: January 3, 2023Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock
-
Patent number: 11175800Abstract: A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.Type: GrantFiled: August 7, 2019Date of Patent: November 16, 2021Assignee: MOXIE SOFTWARE, INC.Inventors: Randy Nasson, Michael Galloway, Prescott Wright, Jonathan Pollock, Shane E. Sherman, Jonathan Lee Bell
-
Publication number: 20210234916Abstract: Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.Type: ApplicationFiled: April 14, 2021Publication date: July 29, 2021Inventors: Michael Galloway, Randy Nasson, Jonathan Lee Bell, Jonathan Pollock
-
Patent number: 10986160Abstract: Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.Type: GrantFiled: February 5, 2020Date of Patent: April 20, 2021Assignee: Moxie Software, Inc.Inventors: Michael Galloway, Randy Nasson, Jonathan Lee Bell, Jonathan Pollock
-
Publication number: 20210107917Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.Type: ApplicationFiled: July 13, 2020Publication date: April 15, 2021Inventors: Tao WU, Liansheng LI, Yi WANG, Pingda REN, Jolanta GREMBECKA, Tomasz CIERPICKI, Szymon KLOSSOWSKI, Jonathan POLLOCK, Dmitry BORKIN
-
Publication number: 20210101908Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.Type: ApplicationFiled: July 30, 2020Publication date: April 8, 2021Inventors: Tao WU, Liansheng LI, Yi WANG, Pingda REN, Jolanta GREMBECKA, Tomasz CIERPICKI, Szymon KLOSSOWSKI, Jonathan POLLOCK, Dmitry BORKIN
-
Patent number: 10781218Abstract: The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: GrantFiled: March 15, 2017Date of Patent: September 22, 2020Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
-
Patent number: 10752639Abstract: The present disclosure provides compounds of Formula (I-E) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: GrantFiled: March 15, 2017Date of Patent: August 25, 2020Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
-
Publication number: 20200177666Abstract: Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.Type: ApplicationFiled: February 5, 2020Publication date: June 4, 2020Inventors: Michael Galloway, Randy Nasson, Jonathan Lee Bell, Jonathan Pollock
-
Publication number: 20200165224Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: ApplicationFiled: June 7, 2018Publication date: May 28, 2020Inventors: Liansheng LI, Tao WU, Jun FENG, Pingda REN, Yi LIU, Jolanta GREMBECKA, Tomasz CIERPICKI, Dmitry BORKIN, Jonathan POLLOCK
-
Patent number: 10588907Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.Type: GrantFiled: June 3, 2016Date of Patent: March 17, 2020Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
-
Publication number: 20200081593Abstract: A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.Type: ApplicationFiled: August 7, 2019Publication date: March 12, 2020Inventors: Randy Nasson, Michael Galloway, Prescott Wright, Jonathan Pollock, Shane E. Sherman, Jonathan Lee Bell
-
Patent number: 10587672Abstract: Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.Type: GrantFiled: August 5, 2015Date of Patent: March 10, 2020Assignee: Moxie Software, Inc.Inventors: Michael Galloway, Randy Nasson, Jonathan Lee Bell, Jonathan Pollock
-
Patent number: 10425501Abstract: A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.Type: GrantFiled: December 9, 2015Date of Patent: September 24, 2019Assignee: Moxie Software, Inc.Inventors: Randy Nasson, Michael Galloway, Prescott Wright, Jonathan Pollock, Shane E. Sherman, Jonathan Lee Bell
-
Patent number: 10246464Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.Type: GrantFiled: September 8, 2015Date of Patent: April 2, 2019Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
-
Publication number: 20190092783Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.Type: ApplicationFiled: March 15, 2017Publication date: March 28, 2019Applicants: Kura Oncology, Inc., The Regents of The University of MichiganInventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
-
Patent number: RE49687Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.Type: GrantFiled: February 2, 2021Date of Patent: October 10, 2023Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu